PTCT
PTC Therapeutics Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
ptc is biopharmaceutical company focused on the discovery and development of orally-administered, proprietary small molecule drugs that target post-transcriptional control processes. while ptc’s discovery programs are directed at targets in multiple therapeutic areas, ptc is focusing particularly on the development and commercialization of treatments for orphan and ultra-orphan disorders. post-transcriptional control processes regulate the rate and timing of protein production and are essential to proper cellular function. ptc’s internally-discovered pipeline addresses multiple therapeutic areas, including neuromuscular disorders, oncology and infectious diseases. for more information on the company, please visit our website www.ptcbio.com.
Market Cap: 2.37 Billion
Primary Exchange: NASDAQ
Website: https://www.ptcbio.com/
Shares Outstanding: 76.6 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 1.4394405075730705
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Ethical Flags
Longest drawdown: 2526 trading days
From: 2015-03-17 To: 2024-03-07
Lowest Point:
BIIB Is For Buy-O-Gen
via: SeekingAlpha at 2019-06-12 06:30:36:000
Let's spell Biogen Buy-o-Gen. Indeed, BIIB seems increasingly appealing at current price. The biotech focuses on discovering, developing, and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets various products for multiple sc… read more...
BIIB Is For Buy-O-Gen
via: SeekingAlpha at 2019-06-12 06:30:36:000
Let's spell Biogen Buy-o-Gen. Indeed, BIIB seems increasingly appealing at current price. The biotech focuses on discovering, developing, and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets various products for multiple sc… read more...
Stoke Therapeutics Files Proposed Terms For IPO
via: SeekingAlpha at 2019-06-11 08:24:08:000
Quick Take Stoke Therapeutics ( STOK ) has filed to raise gross proceeds of $100 million from a U.S. IPO, according to an S-1 registration statement . The firm is developing therapeutics for severe genetic diseases with a focus on dominant loss-of-function [haploinsufficient] diseases of … read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|